HongKong:1477

Ocumension Therapeutics (1477.HK) Reports Revenue Growth in 2020, National Commercial Construction has been started to become outstanding

HONG KONG, March 20, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company,Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the "Group" ), (stock code: 1477.HK), announced its annual results for the year ended31 December 2020 today. Ocumension The...

2021-03-20 18:20 7039

Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases

HONG KONG, Oct. 30, 2020 /PRNewswire/ -- October 30, 2020, Ocumension Therapeutics (1477.HK) announced that the Company has entered into a collaboration and exclusive promotion agreement with Shandong Boan Biological Technology Co. Ltd., a wholly-owned subsidiary of Luye Pharma Group Ltd. to joi...

2020-10-30 10:54 4929

Ocumension Therapeutics Launches Initial Public Offering on Hong Kong Stock Exchange

SHANGHAI, July 10, 2020 /PRNewswire/ -- Ocumension Therapeutics ("Ocumension"), aChina-based ophthalmic pharmaceutical platform company, has today launched its Initial Public Offering (IPO) of the company's stock on The Stock Exchange of Hong Kong (HKEX). Ocumension plans to offer 105,930,000 shar...

2020-07-10 21:55 18306